Core Viewpoint - MediPharm Labs Corp. announces the resignation of Shelley Potts from the Board of Directors and the reappointment of Michael Bumby, highlighting a shift in leadership aimed at supporting the company's strategic priorities in the pharmaceutical cannabinoid sector [1][3]. Group 1: Leadership Changes - Shelley Potts will step down from the Board effective December 31, 2025, after contributing to the company's growth since 2020 [1][3]. - Michael Bumby, who previously served on the Board and was CFO at VIVO Cannabis Inc., will rejoin the Board effective January 1, 2026, bringing extensive experience in finance and governance [1][2]. Group 2: Company Background - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, utilizing a Good Manufacturing Practices certified facility [4]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale domestic GMP License for extracting multiple natural cannabinoids [5]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany, and including Harvest Medical Clinics for patient consultations [6].

Core Viewpoint - MediPharm Labs Corp. announces the resignation of Shelley Potts from the Board of Directors and the reappointment of Michael Bumby, highlighting a shift in leadership aimed at supporting the company's strategic priorities in the pharmaceutical cannabinoid sector [1][3]. Group 1: Leadership Changes - Shelley Potts will step down from the Board effective December 31, 2025, after contributing to the company's growth since 2020 [1][3]. - Michael Bumby, who previously served on the Board and was CFO at VIVO Cannabis Inc., will rejoin the Board effective January 1, 2026, bringing extensive experience in finance and governance [1][2]. Group 2: Company Background - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, utilizing a Good Manufacturing Practices certified facility [4]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale domestic GMP License for extracting multiple natural cannabinoids [5]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany, and including Harvest Medical Clinics for patient consultations [6].

Core Points - MediPharm Labs Corp. has successfully dismissed a $50 million defamation claim against its CEO and Chairman by Apollo Technology Capital Corporation and Nobul Technologies Inc. [1][2][3] - The Ontario Superior Court found that the claims were baseless and that the plaintiffs failed to provide evidence of harm caused by the statements made in a letter related to a proxy contest [3] - The company has also reported unauthorized press releases related to Apollo that were disseminated without its consent [4] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, operating under Good Manufacturing Practices [5] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada and internationally [7]

Core Viewpoint - MediPharm Labs Corp. has successfully dismissed a defamation claim against its CEO and Chairman, reinforcing its legal standing and credibility in the market [1][2][3]. Legal Developments - The Superior Court of Justice in Ontario dismissed a $50 million defamation claim against CEO David Pidduck and Chairman Chris Taves, which was initiated by Apollo Technology Capital Corporation and Nobul Technologies Inc. [1][3] - The court's decision followed a previous dismissal of a related conflict of interest claim against the company's litigation counsel [2]. - The court found that the plaintiffs failed to provide evidence of harm caused by the April 29 letter, which was deemed typical of legal correspondence in such circumstances [3]. Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, operating under Good Manufacturing Practices [5]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for extracting multiple natural cannabinoids [6]. - In 2023, MediPharm expanded its market reach by acquiring VIVO Cannabis Inc., enhancing its presence in Canada, Australia, and Germany [7].

Core Points - MediPharm Labs Corp. will release its third quarter financial results for the three and nine months ended September 30, 2025, before markets open on November 13, 2025 [1] - The executive management team will host a conference call and webcast on the same day at 10:00 a.m. Eastern time to discuss the financial results [2] Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products [5] - The company operates a Good Manufacturing Practices certified facility with ISO standard-built clean rooms, focusing on delivering pure and precision-dosed cannabis products [5] - In 2021, MediPharm received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America with a commercial-scale domestic GMP License for the extraction of multiple natural cannabinoids [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Viewpoint - MediPharm Labs Corp. is set to release its second quarter financial results for the period ending June 30, 2025, on August 14, 2025, before market opening [1] Group 1: Financial Results Announcement - The company will host a conference call and webcast on August 14, 2025, at 10:00 a.m. Eastern time to discuss its financial results [2] - Participants are encouraged to dial in approximately 15 minutes before the start of the call [3] Group 2: Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products [5] - The company operates a Good Manufacturing Practices certified facility with ISO standard-built clean rooms [5] - MediPharm Labs has invested in a research-driven team and state-of-the-art technology for the delivery of precision-dosed cannabis products [5] Group 3: Regulatory and Market Expansion - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America with a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids [6] - In 2023, the company acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Viewpoint - MediPharm Labs Corp. responds to a misleading press release from Apollo Technology Capital Corporation regarding the results of its annual and special meeting of shareholders, emphasizing that the meeting has not yet occurred and results are not available [1][2]. Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products, utilizing a Good Manufacturing Practices certified facility [3]. - The company has invested in a research-driven team and state-of-the-art technology to deliver precision-dosed cannabis products to both domestic and international medical markets [3]. Regulatory Milestones - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, making it the only company in North America with a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids [4]. - This GMP license is a crucial step towards the company's foreign drug manufacturing site registration with the US FDA [4]. Recent Acquisitions - In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded its reach to medical patients in Canada and internationally through various platforms and clinics [5]. - The acquisition included Harvest Medical Clinics in Canada, which provides consultations for medical cannabis education and prescriptions [5]. Compliance and Operations - The company operates in compliance with all applicable laws in the countries where it conducts business [6].

Core Viewpoint - MediPharm Labs Corp. is urging shareholders to support its current strategy and board nominees while rejecting the dissident group's proposals, emphasizing the success of its recent transformation and growth strategy [1][3][5]. Company Strategy and Performance - MediPharm has successfully transformed its operations over the past three years, focusing on strategic business lines, divesting non-core assets, and reducing operating costs, which has led to improved financial performance [3][4]. - The acquisition of VIVO Cannabis Inc. in April 2023 has accelerated international growth and created synergies, contributing to the company's positive trajectory [3][15]. - In Q1 2025, MediPharm reported an 87% revenue increase in the international medical market, achieving positive Adjusted EBITDA for the first time in over five years, with a gross profit margin of 38.7% [4][5]. Shareholder Engagement - The company is encouraging shareholders to vote using the GREEN proxy to support its board nominees and resolutions, emphasizing the importance of each vote [2][11]. - MediPharm has provided resources for shareholders to ensure their votes are counted and to disregard communications from the dissident group [12][18]. Dissident Group's Position - The dissident group, led by Apollo Technology Capital Corp. and former MediPharm CEO Patrick McCutcheon, has proposed alternative directors but has been criticized for lacking a substantive plan and for misrepresentations in their communications [6][7]. - Independent advisory firm ISS has concluded that the dissident group did not present a compelling case for change, reinforcing the company's position [7]. Historical Context - The company highlights the negative performance metrics during McCutcheon's tenure, including a 72% revenue decrease in 2020 and significant operating losses, contrasting this with the current leadership's improvements since 2022 [9][16].

Core Viewpoint - MediPharm Labs Corp. has successfully dismissed a legal application from Apollo Technology Capital Corporation and Nobul Technologies Inc. regarding the appointment of a third-party independent chair for the upcoming shareholder meeting [1][2][3] Legal Proceedings - The Superior Court of Justice in Ontario dismissed the application that sought to appoint an independent chair for the Annual and Special Meeting of Shareholders scheduled for June 16, 2025 [1][2] - The Court found no evidence that MediPharm's proposed meeting chair would act unfairly, thus negating the need for a third-party chair [3] Allegations and Conduct - Apollo's principal, Mr. Regan McGee, made serious allegations against MediPharm, including securities fraud and breach of fiduciary duty, and threatened to release damaging statements [3] - Mr. McGee initiated a lawsuit claiming $50 million in damages against MediPharm and its senior officers, but later withdrew certain claims and agreed to terms that included a declaration of no conflict of interest for the Company's legal counsel [3] Shareholder Voting Guidance - MediPharm encourages shareholders to vote using only the GREEN proxy or voting instruction card to support the Board's nominees and resolutions [4][5] - Shareholders are advised to contact their brokers to obtain their control numbers for voting and to disregard any communications from dissident parties [6] Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis products [7][8] - The company holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [9] - In 2023, MediPharm expanded its operations through the acquisition of VIVO Cannabis Inc., enhancing its reach in the medical cannabis market [10]

Core Viewpoint - Institutional Shareholder Services (ISS) recommends that MediPharm shareholders vote for the company's nominees for the Board of Directors, stating that the dissident, Apollo, has not presented a compelling case for change [2][6]. Group 1: ISS Report Findings - The ISS Report concludes that Apollo's claims lack sufficient evidence, highlighting that since Q2 2022, quarterly revenues have more than doubled, adjusted EBITDA has improved from a $6.3 million loss to a $0.1 million gain, and gross margins have expanded by 50.9 percentage points [4][5]. - The report indicates that MediPharm has shown multiple years of improving financial results, particularly under CEO David Pidduck's leadership, and has a logical strategy focusing on higher margin international markets [4][5]. - The ISS Report states that the company has generally outperformed its peers and experienced a clear operational turnaround, contradicting the dissident's claims of peril [4][5]. Group 2: Recommendations for Shareholders - ISS recommends that shareholders vote for the resolution to fix the number of directors at seven, approve MNP LLP as auditors, and authorize the Board to fix their remuneration [6]. - Shareholders are advised to vote against the resolution to approve all unallocated awards under the Company's equity incentive plan [6]. - MediPharm urges shareholders to use the GREEN proxy or voting instruction form to support all of the Company's nominees and resolutions [7][8]. Group 3: Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and has a GMP-certified facility [9]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale domestic GMP License for cannabinoid extraction [10]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada and internationally [11].